Preliminary data for the SIRPα-Fc fusion protein IMM01 in combination with Aza showed promising efficacy and tolerability in patients with treatment-naive chronic myelomonocytic leukemia (CMML) and higher-risk myelodysplastic syndrome (HR-MDS). This evidence concerns the gene SIRPA and chronic myelomonocytic leukemia.